Biotech stocks start to come back into favour

Healthcare stocks in the US remain depressed but within that sector strong momentum remains for biotech companies. The broader healthcare businesses have become a casualty of the global focus on strong growth stocks like technology and telecoms. Meanwhile, healthcare reforms that are expected amid the US presidential election campaign have exacerbated underperformance in the sector. The biotech companies, which focuses on genetic rather than chemical-based products, continue to gather momentum. During 1999, the S&P Biotech Sub Sector Index was up 130% in dollar terms, and has risen an e...